Sector News

Bayer completes EUR 1 Bln sale of diabetes care business

January 5, 2016
Life sciences

(RTTNews) – German conglomerate Bayer AG Tuesday said it closed on its previously announced agreement to sell its Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd. The total consideration for the transaction was around 1 billion euros or 132 billion Japanese yen.

The sale includes Contour portfolio of blood glucose monitoring meters and strips, as well as other products such as Breeze2, Elite and Microlet lancing devices.

Panasonic Healthcare is backed by funds sponsored by investment firm KKR (KKR) and Japanese consumer electronics giant Panasonic Corp. (PCRFF, PCRFY). The new stand-alone Diabetes Care business is named Ascensia Diabetes Care Holdings and is headquartered in Basel, Switzerland.

Bayer Diabetes Care or BDC, is a provider of blood glucose monitoring systems to people with diabetes and healthcare professionals around the world. Bayer’s Diabetes Care business accounted for 909 million euros in sales in 2014.

It was in June last year that Panasonic Healthcare agreed to acquire the diabetes devices business from Bayer for 1.02 billion euros or $1.16 billion to create a truly global diabetes care solutions business.

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

How can we help you?

We're easy to reach